Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.
Claris Biotherapeutics has raised $5.6M in total funding. The most recent round was Debt Financing. The last funding was announced in March 2025.
Claris Biotherapeutics's investors include RA Capital Management, Janus Henderson Investors, Catalio Capital Management, Novo Holdings, Mass General Brigham Ventures.
Claris Biotherapeutics is headquartered in Jersey City, United States.
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.
Claris Biotherapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Claris Biotherapeutics — Funding & Investors." VCBacked, March 7, 2025, https://www.vcbacked.co/company/claris-biotherapeutics. Accessed July 31, 2026.
VCBacked. (2025). Claris Biotherapeutics — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/claris-biotherapeutics
{{cite web |title=Claris Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/claris-biotherapeutics |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated